# Ruxolitinib Phosphate (Opzelura)

Source: https://ourhealthnetwork.com/drugs/ruxolitinib-phosphate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Ruxolitinib Phosphate?

Ruxolitinib Phosphate (brand name: Opzelura) is a kinase inhibitor taken topical. It is prescribed to treat primary myelofibrosis, polycythemia vera. Across the United States, 4,000 doctors prescribe Ruxolitinib to approximately 5,000 Medicare patients.

## Brand names

Opzelura

## Indications

Ruxolitinib Phosphate is prescribed for the treatment of primary myelofibrosis and polycythemia vera.

## Conditions treated

- [Primary Myelofibrosis](https://ourhealthnetwork.com/conditions/primary-myelofibrosis)
- [Polycythemia Vera](https://ourhealthnetwork.com/conditions/polycythemia-vera)

## Mechanism of action

Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulati

## Drug classification

- Established Pharmacologic Class: kinase inhibitors
- Route of administration: TOPICAL

## Common side effects

bronchitis, diarrhea, ear infection, eosinophil count increased, folliculitis, nasopharyngitis, rhinorrhea, tonsillitis

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)